WST WEST PHARMACEUTICAL SERVICES INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 105770 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.6%
TTM net income YoY29.9%
TTM EPS YoY32.0%
Revenue 3-yr CAGR5.1%
Net income 3-yr CAGR4.5%
Margins
Gross margin37.6%
Operating margin23.0%
Net margin18.8%
FCF margin13.3%
EBITDA margin28.4%
Returns
ROE21.2%
ROA15.6%
ROIC (approx.)23.0%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.07x
Current ratio2.82x
Interest coverage96.32x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio-0.4%
Payout ratio9.8%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $874.50M | $872.30M | $844.90M | $805.00M | $804.60M | $766.50M | $698.00M | $748.80M |
| Cost of revenue | $527.10M | $543.10M | $548.50M | $501.10M | $510.30M | $492.60M | $466.10M | $475.20M |
| Gross profit | $347.40M | $329.20M | $296.40M | $303.90M | $294.30M | $273.90M | $231.90M | $273.60M |
| R&D expense | $18.30M | $19.70M | $15.80M | $21.80M | $17.10M | $19.10M | $16.30M | $18.50M |
| SG&A expense | $112.90M | $117.60M | $99.50M | $107.00M | $102.70M | $95.90M | $88.00M | $85.30M |
| Operating income | $267.40M | $179.10M | $177.10M | $156.60M | $167.60M | $153.70M | $107.00M | $159.60M |
| Interest expense | $3.80M | $2.60M | $1.90M | -$200,000 | $200,000 | $100,000 | $400,000 | -$800,000 |
| Pretax income | $267.70M | $180.10M | $180.10M | $161.50M | $171.90M | $157.00M | $110.50M | $164.90M |
| Income tax | $58.00M | $32.20M | $44.70M | $33.30M | $34.00M | $30.20M | $24.10M | $36.80M |
| Net income | $214.00M | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | $89.80M | $130.10M |
| EBITDA | $313.30M | $225.30M | $222.30M | $203.60M | $210.60M | $195.10M | $147.00M | $200.30M |
| EPS (basic) | 3.04 | 2.17 | 1.93 | — | 1.94 | 1.82 | 1.24 | — |
| EPS (diluted) | 3.02 | 2.15 | 1.92 | — | 1.92 | 1.82 | 1.23 | — |
| Dividends declared per share | 0.22 | — | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | — |
| Weighted avg. shares (diluted) | 70.80M | 71.30M | 72.40M | — | 72.60M | 72.50M | 73.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $464.10M | $435.80M | $521.40M | $791.30M | $628.50M | $509.70M | $404.20M | $484.60M |
| Receivables | $748.20M | $712.00M | $685.60M | $574.40M | $625.00M | $582.40M | $543.60M | $552.50M |
| Inventory | $464.70M | $447.40M | $452.60M | $443.90M | $438.00M | $421.10M | $388.70M | $377.00M |
| Current assets | $1.82B | $1.81B | $1.83B | $1.98B | $1.82B | $1.68B | $1.46B | $1.54B |
| PP&E, net | $1.67B | $1.69B | $1.70B | $1.73B | $1.74B | $1.72B | $1.63B | $1.58B |
| Goodwill | $108.70M | $108.70M | $109.20M | $109.90M | $110.60M | $110.90M | $107.50M | $106.00M |
| Intangibles | $6.20M | $6.40M | $7.00M | $7.70M | $8.90M | $9.70M | $10.00M | $10.80M |
| Total assets | $4.06B | $4.08B | $4.11B | $4.27B | $4.11B | $3.95B | $3.62B | $3.64B |
| Current liabilities | $644.30M | $640.50M | $674.00M | $654.90M | $635.40M | $604.60M | $526.70M | $550.40M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $202.90M | $202.90M | $202.80M | $202.80M | $202.70M | $202.60M | $202.60M | $202.60M |
| Total debt | $202.90M | $202.90M | $202.80M | $202.80M | $202.70M | $202.60M | $202.60M | $202.60M |
| Total liabilities | $1.09B | $1.09B | $1.12B | $1.09B | $1.05B | $1.02B | $935.10M | $961.10M |
| Shareholders' equity | $2.97B | $2.99B | $2.99B | $3.18B | $3.05B | $2.93B | $2.68B | $2.68B |
| Net debt | -$261.20M | -$232.90M | -$318.60M | -$588.50M | -$425.80M | -$307.10M | -$201.60M | -$282.00M |
| Shares outstanding | 69.80M | 70.40M | 70.90M | 72.00M | 71.90M | 71.90M | 71.80M | 72.30M |
| Cash flow statement | ||||||||
| Operating cash flow | $189.50M | $124.00M | $89.90M | $251.10M | $197.20M | $177.10M | $129.40M | $190.10M |
| Capital expenditure | $39.10M | $43.20M | $42.70M | $76.10M | $63.30M | $75.20M | $71.30M | $104.90M |
| Free cash flow | $150.40M | $80.80M | $47.20M | $175.00M | $133.90M | $101.90M | $58.10M | $85.20M |
| Investing cash flow | $78.90M | -$43.20M | -$42.70M | -$76.10M | -$63.30M | -$75.20M | -$71.30M | -$104.80M |
| Financing cash flow | -$241.80M | -$164.80M | -$308.70M | -$11.70M | -$11.50M | -$14.90M | -$147.00M | -$68.90M |
| Depreciation & amortization | $45.90M | $46.20M | $45.20M | $47.00M | $43.00M | $41.40M | $40.00M | $40.70M |
| Stock-based compensation | $4.30M | $10.90M | $6.60M | $6.70M | $8.40M | $7.40M | $1.30M | $4.30M |
| Dividends paid | $15.50M | $15.70M | $15.80M | $15.80M | $15.10M | $15.10M | $15.20M | $15.30M |
| Share buybacks | $231.00M | $156.70M | $297.60M | $0 | $0 | $500,000 | $133.50M | $54.40M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.